Protalix BioTherapeutics, Inc. (DE) Common Stock
Key Metrics
Market Snapshot
About
Protalix BioTherapeutics, Inc. (DE) Common Stock (PLX) is a biopharmaceutical company headquartered in Hackensack, New Jersey. It develops, produces, and commercializes recombinant therapeutic proteins, and is best known for its ProCellEx system, a plant cell-based platform used to express these proteins.
The company already markets two approved products. Elelyso is used to treat Gaucher disease, and Elfabrio is approved for adult patients with a confirmed diagnosis of Fabry disease. Both conditions are rare inherited disorders, and the products reflect the company's focus on protein-based treatments for these diseases produced through its plant cell technology.
Protalix is also advancing earlier-stage candidates. PRX-115 is a plant cell expressed recombinant PEGylated uricase in a Phase 2 trial for gout. PRX-119 is a plant cell expressed PEGylated recombinant human DNase I candidate being developed for diseases involving neutrophil extracellular traps. These programs aim to extend the use of the ProCellEx platform into additional conditions beyond the company's current approved therapies.
The company works with a number of outside organizations. It has agreements and partnerships with Pfizer, Fundacao Oswaldo Cruz, and Chiesi Farmaceutici S.p.A., and it holds a strategic partnership with Secarna Pharmaceuticals GmbH and Co KG. These relationships support the development and commercialization of its products in different regions and indications. By combining marketed treatments for rare diseases with a pipeline of new candidates and a distinctive plant cell expression approach, Protalix BioTherapeutics, Inc. centers its business on producing therapeutic proteins and bringing them to patients through both its own efforts and collaborations.